Pierre Blier

ORCID: 0000-0003-1881-2421
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Neurotransmitter Receptor Influence on Behavior
  • Treatment of Major Depression
  • Neuroscience and Neuropharmacology Research
  • Physiological and biochemical adaptations
  • Receptor Mechanisms and Signaling
  • Aquaculture Nutrition and Growth
  • Tryptophan and brain disorders
  • Functional Brain Connectivity Studies
  • Mitochondrial Function and Pathology
  • Electroconvulsive Therapy Studies
  • Bipolar Disorder and Treatment
  • Mental Health Research Topics
  • Fish Ecology and Management Studies
  • Marine Bivalve and Aquaculture Studies
  • Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Obsessive-Compulsive Spectrum Disorders
  • Aquaculture disease management and microbiota
  • Adipose Tissue and Metabolism
  • Reproductive biology and impacts on aquatic species
  • Memory and Neural Mechanisms
  • Attention Deficit Hyperactivity Disorder
  • Pharmacological Receptor Mechanisms and Effects
  • Aquatic Invertebrate Ecology and Behavior
  • Genetics, Aging, and Longevity in Model Organisms
  • Nicotinic Acetylcholine Receptors Study

Université du Québec à Rimouski
2016-2025

University of Ottawa
2016-2025

Royal Ottawa Mental Health Centre
2016-2025

McGill University
1998-2025

Mental Health Research Canada
2007-2024

Ottawa Hospital
2023

Carleton University
2022

Université Laval
1988-2022

Biologie des Organismes et Écosystèmes Aquatiques
2022

Indoc Research
2020

To investigate the contribution of individual serotonin (5-hydroxytryptamine; 5-HT) receptors to mood control, we have used homologous recombination generate mice lacking specific serotonergic receptor subtypes. In present report, demonstrate that without 5-HT1A display decreased exploratory activity and increased fear aversive environments (open or elevated spaces). knockout also exhibited a immobility in forced swim test, an effect commonly associated with antidepressant treatment....

10.1073/pnas.95.24.14476 article EN Proceedings of the National Academy of Sciences 1998-11-24

Controlled studies have shown short-term efficacy of esketamine for treatment-resistant depression (TRD), but long-term effects remain to be established.To assess the nasal spray plus an oral antidepressant compared with placebo in delaying relapse depressive symptoms patients TRD stable remission after induction and optimization course antidepressant.In this phase 3, multicenter, double-blind, randomized withdrawal study conducted from October 6, 2015, February 15, 2018, at outpatient...

10.1001/jamapsychiatry.2019.1189 article EN JAMA Psychiatry 2019-06-05

Abstract Background About one-third of patients with depression fail to achieve remission despite treatment multiple antidepressants and are considered have treatment-resistant depression. Methods This Phase 3, double-blind, multicenter study enrolled adults moderate-to-severe nonresponse ≥2 in the current episode. Eligible (N = 346) were randomized (1:1:1) twice-weekly nasal spray (esketamine [56 or 84 mg] placebo) plus a newly initiated, open-label, oral antidepressant taken daily for 4...

10.1093/ijnp/pyz039 article EN cc-by-nc The International Journal of Neuropsychopharmacology 2019-07-09

Abstract The sustained administration of the 5‐HT 1A agonist gepirone (15 mg/kg/day, s.c.) in rat produced an initial decrease firing activity dorsal raphe neurons which was followed by a progressive recovery to normal after 14 days treatment. At this point time, effect intravenous lysergic acid diethylamide (LSD) on markedly reduced, whereas those 8‐hydroxy‐2‐N, N‐propylamino‐tetralin (8‐OH‐DPAT) and were unchanged; however, responsiveness direct microintophoretic application 5‐HT, LSD,...

10.1002/syn.890010511 article EN Synapse 1987-01-01

Results of electrophysiological single-cell recording studies suggest that most, if not all, types antidepressant treatments increase 5-hydroxytryptamine (5-HT) neurotransmission. Tricyclic antidepressants, electroconvulsive shock treatment, mianserin, adinazolam, and possibly sleep deprivation may exert their therapeutic effect through sensitization postsynaptic neurons to 5-HT. Serotonin reuptake blockers relieve depression an increased efficacy the presynaptic element resulting from a...

10.1097/00004714-198712001-00003 article EN Journal of Clinical Psychopharmacology 1987-12-01

Subanesthetic ketamine doses have been shown to rapid yet transient antidepressant effects in patients with treatment-resistant depression, which may be prolonged by repeated administration. The purpose of this study was evaluate the a single infusion, series infusions, and prolongation response maintenance infusions.Forty-one participants depression completed single-site randomized double-blind crossover comparison infusions midazolam (an active placebo control). After relapse depressive...

10.1176/appi.ajp.2018.18070834 article EN American Journal of Psychiatry 2019-03-29

Various classes of antidepressant medications generally induce remission major depressive disorder in only about one-third patients. In a previous study using mirtazapine or paroxetine alone combination from treatment initiation, the rate patients who remitted within 6-week period was twice that either drug alone. this double-blind study, authors sought to produce evidence for superiority different combinations drugs initiation.Patients (N=105) meeting DSM-IV criteria were randomly assigned...

10.1176/appi.ajp.2009.09020186 article EN American Journal of Psychiatry 2009-12-16

Anatomical studies have established the existence of reciprocal relationships between main population monoamine, serotonin (5-HT), norepinephrine (NE) and dopamine (DA) neurons in brain. The present study was thus conducted to examine firing activity 5-HT NE DA-depleted rats, as well DA 5-HT- or NE-depleted rats. selective lesion elicited by 6-hydroxydopamine (6-OHDA) decreased spontaneous dorsal raphe (DR) nucleus 60%, revealing excitatory effect input on these neurons. In contrast,...

10.1017/s1461145707008383 article EN The International Journal of Neuropsychopharmacology 2008-01-21

Abstract Antidepressants (ADs) are the most common treatment for major depressive disorder (MDD). However, only ∼30% of patients experience adequate response after a single AD trial, and this variability remains poorly understood. Here, we investigated microRNAs (miRNAs) as biomarkers using small RNA-sequencing in paired samples from MDD enrolled large, randomized placebo-controlled trial duloxetine collected before 8 weeks treatment. Our results revealed differential expression miR-146a-5p,...

10.1038/ncomms15497 article EN cc-by Nature Communications 2017-05-22

Background The Canadian Network for Mood and Anxiety Treatments (CANMAT) last published clinical guidelines the management of major depressive disorder (MDD) in 2016. Owing to advances field, an update was needed incorporate new evidence provide revised recommendations assessment MDD adults. Methods CANMAT convened a editorial group comprised academic clinicians patient partners. A systematic literature review conducted, focusing on reviews meta-analyses since 2016 guidelines....

10.1177/07067437241245384 article EN cc-by The Canadian Journal of Psychiatry 2024-05-06
Coming Soon ...